Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost
Source: medpagetoday.com
Stay updated with breaking news from Gabe Sonke. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
No PFS, OS benefit with first-line versus second-line CDK4/6 inhibition, more toxicity, cost